BridgeBio Pharma Eulerpool Vijesti

BridgeBio Pharma Aktie News

BridgeBio Pharma prate mnogi novinari i investitori širom svijeta. Najnovije BridgeBio Pharma vijesti prikupljamo ovdje.

• 17. prosinca ·

  SeekingAlpha
  The Take On Tyra Biosciences
• 13. prosinca ·

  Yahoo
  Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
• 26. studenoga ·

  Yahoo
  BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
• 26. studenoga ·

  SeekingAlpha
  Invesco Health Care Fund Q3 2024 Commentary
• 25. studenoga ·

  Yahoo
  FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
• 24. studenoga ·

  SeekingAlpha
  BridgeBio: Next Chapter Begins After Attruby Approval
• 23. studenoga ·

  Yahoo
  Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
• 21. studenoga ·

  Yahoo
  Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?
• 19. studenoga ·

  Yahoo
  The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
• 18. studenoga ·

  Yahoo
  Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months